Opinion of the Transparency Council – nilotinib
At its meeting on 5 May 2025, the Transparency Council adopted opinion No. 73/2025 on the appropriateness of changing the reimbursement category of the active substance nilotinib and including it in the reimbursement scheme for a new indication.